Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Dong Ho Lee 4 Articles
Is Percutaneous Endoscopic Gastrostomy Acceptable in Centenarian Patients?
Cheol Min Shin, Dong Ho Lee
Clin Endosc 2018;51(1):1-2.   Published online January 31, 2018
DOI: https://doi.org/10.5946/ce.2018.018
PDFPubReaderePub
  • 5,481 View
  • 137 Download
Close layer
Correlation of Endoscopic Findings of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma with Recurrence after Complete Remission
Chang Min Lee, Dong Ho Lee, Byung Kyu Ahn, Jae Jin Hwang, Hyuk Yoon, Young Soo Park, Cheol Min Shin, Nayoung Kim
Clin Endosc 2017;50(1):51-57.   Published online March 24, 2016
DOI: https://doi.org/10.5946/ce.2016.015
AbstractAbstract PDFPubReaderePub
Background
/Aims: In gastric mucosa-associated lymphoid tissue (MALT) lymphoma, the clinical significance of various endoscopic findings has not yet been determined. This study aimed to compare the time to complete remission (CR) and relapse-free survival (RFS) in gastric MALT lymphoma based on endoscopic findings.
Methods
In this single-center retrospective cohort study, the medical records of 122 consecutive adult patients with gastric MALT lymphoma were collected over a period of 12 years. CR was defined by the absence of macroscopic or microscopic features of lymphoma on two subsequent follow-ups. Relapse was clinically defined by a positive endoscopic biopsy after CR.
Results
The median time to CR did not differ significantly between treatment methods. However, it was significantly longer in the group with polypoid endoscopic appearance than in the groups with diffuse infiltration or ulceration (7.83, 3.43, and 3.10 months, respectively; p=0.003). Six patients relapsed after CR. Kaplan-Meier analysis showed that RFS differed significantly between groups based on Ann Arbor staging, treatment methods, and initial endoscopic findings.
Conclusions
In gastric MALT lymphoma, the endoscopically defined polypoid type was characterized by a longer duration to CR, with a higher likelihood of recurrence, compared to the endoscopically defined diffuse infiltration or ulceration types.

Citations

Citations to this article as recorded by  
  • A Case of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma with Special Endoscopic Morphology
    Xin Sun, Yanbo Zhen, Pan Pan, Liang Liu
    Journal of Digestive Endoscopy.2024;[Epub]     CrossRef
  • Characteristic endoscopic findings of gastrointestinal malignant lymphomas other than mucosa-associated lymphoid tissue lymphoma
    T Kanno, T Katano, T Shimura, R Nishigaki, Y Kojima, M Sasaki, Y Okuda, N Sugimura, S Fukusada, Y Mizuno, H Iwasaki, H Nishie, M Tanaka, K Ozeki, E Kubota, S Tanida, H Kataoka
    Acta Gastro Enterologica Belgica.2022; 85(3): 477.     CrossRef
  • Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
    Shotaro Nakamura, Mariko Hojo
    Journal of Clinical Medicine.2022; 12(1): 120.     CrossRef
  • Normal gastrointestinal tract inflammatory cells and review of select benign hematolymphoid proliferations
    Jennifer Y. Ju, Edward B. Stelow, Elizabeth L. Courville
    Seminars in Diagnostic Pathology.2021; 38(4): 6.     CrossRef
  • Optimal Initial Workup in Patients With Superficial Primary Gastric MALT Lymphoma
    Hee Kyong Na, Sung Hyun Won, Jeong Hoon Lee, Ga Hee Kim, Kee Wook Jung, Ji Yong Ahn, Do Hoon Kim, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung
    Journal of Clinical Gastroenterology.2021; 55(9): 785.     CrossRef
  • Endoscopic features and clinical outcomes of colorectal mucosa-associated lymphoid tissue lymphoma
    Min Kyung Jeon, Hoonsub So, Jooryung Huh, Hee Sang Hwang, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kee Don Choi, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon
    Gastrointestinal Endoscopy.2018; 87(2): 529.     CrossRef
  • Endoscopic Findings of Gastric Extranodal Marginal Zone B-Cell Mucosa-Associated Lymphoid Tissue Lymphoma
    Sang Kil Lee
    Clinical Endoscopy.2017; 50(1): 1.     CrossRef
  • 9,944 View
  • 225 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
Low Grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Clinicopathological Factors Associated with Helicobacter pylori Eradication and Tumor Regression
Yoon Jin Choi, Dong Ho Lee, Ji Yeon Kim, Ji Eun Kwon, Jae Yeon Kim, Hyun Jin Jo, Cheol Min Shin, Hyun Young Kim, Young Soo Park, Nayoung Kim, Hyun Chae Jung, In Sung Song
Clin Endosc 2011;44(2):101-108.   Published online December 31, 2011
DOI: https://doi.org/10.5946/ce.2011.44.2.101
AbstractAbstract PDFPubReaderePub
Background/Aims

Eradication of Helicobacter pylori is widely accepted as initial therapy for low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, approximately 20% of patients with this disease are not responsive to H. pylori eradication therapy. The aim of this study was to assess remission and relapse rates of low-grade gastric MALT lymphoma after H. pylori eradication and identify the clinical factors that affect remission.

Methods

Thirty-nine patients diagnosed with gastric MALT lymphoma (May 2003 to May 2010) were retrospectively analyzed.

Results

Of the 39 patients, 30 (77%) had a H. pylori infection. There were 35/39 (90%) patients with stage I. Among stage I, 25 patients with the infection underwent eradication therapy and 22/25 (88%) achieved remission. The total regression rate with eradication only in stage I was 24/28 (86%). The median time to remission was 98 days (range, 22 to 397 days). Age, tumor location, invasion depth, H. pylori burden, and severity of mononuclear leukocyte and neutrophil infiltration were not related to remission. However, patients with less neutrophil infiltration were more likely to achieve a successful first H. pylori eradication (p=0.049).

Conclusions

The results show that the rate of low-grade gastric MALT lymphoma regression (86%) with H. pylori eradication alone was higher than that in Western studies (77.8%) and that neutrophil infiltration was inversely related to success of the first H. pylori eradication procedure.

Citations

Citations to this article as recorded by  
  • Effectiveness of Helicobacter pylori eradication in the treatment of early-stage gastric mucosa-associated lymphoid tissue lymphoma: An up-to-date meta-analysis
    Fabian Fellipe Bueno Lemos, Caroline Tianeze de Castro, Mariana Santos Calmon, Marcel Silva Luz, Samuel Luca Rocha Pinheiro, Clara Faria Souza Mendes dos Santos, Gabriel Lima Correa Santos, Hanna Santos Marques, Henrique Affonso Delgado, Kádima Nayara Tei
    World Journal of Gastroenterology.2023; 29(14): 2202.     CrossRef
  • Efficacy of eradication therapy in Helicobacter pylori‐negative gastric mucosa‐associated lymphoid tissue lymphoma: A meta‐analysis
    Kyoungwon Jung, Do Hoon Kim, Hyun Il Seo, Eun Jeong Gong, Chang Seok Bang
    Helicobacter.2021;[Epub]     CrossRef
  • Clinical efficacy of the modified Helicobacter pylori eradication therapy for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a meta analysis
    Ya-Lin Xie, Chun-Yan He, Si-Qi Wei, Wen-Ju Guan, Zheng Jiang
    Chinese Medical Journal.2020; 133(11): 1337.     CrossRef
  • Clinical Efficacy of Radiotherapy inHelicobacter pyloriNegative or Unresponsive to Eradication Therapy Primary Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
    Byung Sam Park, Si Hyung Lee
    The Korean Journal of Gastroenterology.2019; 73(1): 19.     CrossRef
  • Endoscopic features aiding the diagnosis of gastric mucosa-associated lymphoid tissue lymphoma
    Byung Sam Park, Si Hyung Lee
    Yeungnam University Journal of Medicine.2019; 36(2): 85.     CrossRef
  • Bone marrow involvement is not associated with the clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma
    Eun Jeong Gong, Ji Yong Ahn, Hwoon-Yong Jung, Kyoungwon Jung, Charles J. Cho, Hee Kyong Na, Kee Wook Jung, Do Hoon Kim, Jeong Hoon Lee, Kee Don Choi, Ho June Song, Gin Hyug Lee, Jin-Ho Kim, Dok Hyun Yoon
    Scandinavian Journal of Gastroenterology.2016; 51(8): 942.     CrossRef
  • Helicobacter pyloriEradication Therapy Is Effective as the Initial Treatment for Patients withH. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
    Eun Jeong Gong, Ji Yong Ahn, Hwoon-Yong Jung, Hyungchul Park, Young Bo Ko, Hee Kyong Na, Kee Wook Jung, Do Hoon Kim, Jeong Hoon Lee, Kee Don Choi, Ho June Song, Gin Hyug Lee, Jin-Ho Kim
    Gut and Liver.2016; 10(5): 706.     CrossRef
  • Antisecretory medication is associated with decreased Helicobacter pylori detection in gastric marginal zone lymphoma
    Kurt B. Schaberg, Mark F. Evans, Rebecca Wilcox, Michael R. Lewis
    Annals of Diagnostic Pathology.2015; 19(6): 397.     CrossRef
  • A Polypoid Mucosa-Associated Lymphoid Tissue Lymphoma of the Stomach Treated with Endoscopic Polypectomy
    Shin Young Min, Jun Haeng Lee, Poong-Lyul Rhee
    Clinical Endoscopy.2013; 46(6): 647.     CrossRef
  • 8,320 View
  • 53 Download
  • 9 Crossref
Close layer
Dual Therapy Trial Using Esomeprazole and Amoxicillin as Third-line Rescue Therapy for Helicobacter pylori Infection
Hyun Kyung Park, Dong Ho Lee, Seungchul Suh, Pyoung Ju Seo, Nayoung Kim, Sook-Hyang Jeong, Jin-Wook Kim, Jin-Hyeok Hwang, Young Soo Park, Sang Hyub Lee, Cheol Min Shin
Clin Endosc 2011;44(1):33-37.   Published online September 30, 2011
DOI: https://doi.org/10.5946/ce.2011.44.1.33
AbstractAbstract PDFPubReaderePub
Background/Aims

The purpose of this study was to evaluate the efficacy and tolerability of dual therapy consisting of esomeprazole and amoxicillin as a rescue therapy for Helicobacter pylori infection.

Methods

From December 2009 to August 2010, 21 patients who experienced two consecutive eradication failures were included. They received esomeprazole (40 mg, b.i.d.) and amoxicillin (1,000 mg, b.i.d.) for 14 days as a third eradication regimen. Compliance and side effects were determined from an interview. H. pylori status was evaluated using the 13C urea breath test at least 6 weeks after treatment.

Results

The mean age of the patients was 59 years and included 52% males. Indications for treatment were functional dyspepsia (61.9%), peptic ulcer disease (28.6%), and gastric adenoma (9.5%). H. pylori was eradicated in 14 of 21 (66.7%) patients. Minor side effects were reported in three of the 21 patients (14.3%). These side effects consisted mainly of nausea and epigastric discomfort.

Conclusions

A 2-week course of dual therapy failed to show satisfactory results in third-line H. pylori eradication, but it was very safe and tolerable. Therefore, dual therapy constitutes an encouraging empirical strategy for the elderly and infirm patients with multiple previous eradication failures.

Citations

Citations to this article as recorded by  
  • Dual therapy for Helicobacter pylori infection
    Miao Duan, Jing Liu, Xiuli Zuo
    Chinese Medical Journal.2023;[Epub]     CrossRef
  • Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience
    Bei Tan, Jyh-Chin Yang, Carol L. Young, Shrinivas Bishu, Stephanie Y. Owyang, Mohamad El-Zaatari, Min Zhang, Helmut Grasberger, Jia-ming Qian, John Y. Kao
    Digestive Diseases and Sciences.2018; 63(2): 437.     CrossRef
  • Treatment of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis
    Sang Wook Lee, Hyun Jung Kim, Jae Gyu Kim
    Journal of Korean Medical Science.2015; 30(8): 1001.     CrossRef
  • 6,819 View
  • 48 Download
  • 3 Crossref
Close layer

Clin Endosc : Clinical Endoscopy Twitter Facebook
Close layer
TOP